Table 2 Clinical outcomes for patients initiating biologics treatment under the enhanced pathway.
From: Mixed-methods evaluation of an enhanced asthma biologics clinical pathway in the West Midlands UK
Pre-biologics | Post-biologics | |||||
|---|---|---|---|---|---|---|
Mean rate/month (SD) | Range | Mean rate/month (SD) | Range | % change in mean rate | p-value | |
PRESCRIBING | ||||||
Inhaled corticosteroids | 1.37 (0.55) | 0.5–2.3 | 1.48 (0.52) | 0.4–2.9 | +8% | p = 0.210 |
Short-acting beta agonists | 0.93 (0.46) | 0.2–2.2 | 0.76 (0.51) | 0.0–2.2 | −18% | p = 0.037 |
Oral corticosteroids | 0.37 (0.37) | 0.0–1.3 | 0.12 (0.22) | 0.0–0.8 | −60% | p < 0.001 |
EXACERBATIONS | ||||||
Exacerbations | 0.36 (0.26) | 0.0–1.0 | 0.13 (0.22) | 0.0–0.8 | −64% | p < 0.001 |
HOSPITAL USE | ||||||
Admissions | 0.12 (0.16) | 0.0–0.8 | 0.01 (0.36) | 0.0–0.2 | −92% | p < 0.001 |
ASTHMA CONTROL | Mean score (SD) | Mean score (SD) | ||||
ACQ6 scores | 3.31 (1.34) | 0.6–5.4 | 1.89 (1.36) | 0.0–5.0 | 40% improvement | p < 0.001 |
